From fcb806d872af178b13ab31b90287ff53552cb0a7 Mon Sep 17 00:00:00 2001 From: kevin olson Date: Sun, 8 Sep 2024 22:17:22 -0500 Subject: [PATCH 1/2] =?UTF-8?q?=F0=9F=93=9D=20restructuring=20the=20conten?= =?UTF-8?q?t?= MIME-Version: 1.0 Content-Type: text/plain; charset=UTF-8 Content-Transfer-Encoding: 8bit --- content/1.research/{index.md => 1.index.md} | 19 ++----- content/1.research/1.peptides/1.overview.md | 51 ------------------- content/1.research/1.peptides/_index.md | 14 ----- .../{1.peptides => }/2.tirzepatide.md | 0 .../{1.peptides => }/3.cagrilintide.md | 0 .../{1.peptides => }/4.retatrutide.md | 0 6 files changed, 5 insertions(+), 79 deletions(-) rename content/1.research/{index.md => 1.index.md} (68%) delete mode 100644 content/1.research/1.peptides/1.overview.md delete mode 100644 content/1.research/1.peptides/_index.md rename content/1.research/{1.peptides => }/2.tirzepatide.md (100%) rename content/1.research/{1.peptides => }/3.cagrilintide.md (100%) rename content/1.research/{1.peptides => }/4.retatrutide.md (100%) diff --git a/content/1.research/index.md b/content/1.research/1.index.md similarity index 68% rename from content/1.research/index.md rename to content/1.research/1.index.md index fc740b0..ee8cd60 100644 --- a/content/1.research/index.md +++ b/content/1.research/1.index.md @@ -1,23 +1,14 @@ --- -title: Peptide Research +title: Overview description: Explore cutting-edge peptide therapeutics for metabolic disorders, including GLP-1 agonists, dual and triple receptor agonists, and innovative treatments for obesity and diabetes. -navigation: false +position: 1 --- ::card-group - ::card - --- - title: Overview - to: /research/peptides/overview - icon: i-mdi-file-document-box-search - --- - Recent advancements in peptide therapies have led to the development of three promising treatments for obesity and type 2 diabetes: tirzepatide, retatrutide, and cagrilintide. - :: - ::card --- title: Tirzepatide - to: /research/peptides/tirzepatide + to: /research/tirzepatide icon: i-mdi-medication --- A dual GIP/GLP-1 receptor agonist that significantly improves glycemic control and promotes substantial weight loss in patients with type 2 diabetes. @@ -26,7 +17,7 @@ navigation: false ::card --- title: Retatrutide - to: /research/peptides/retatrutide + to: /research/etatrutide icon: i-mdi-medication --- An innovative triple-agonist peptide that targets GIP, GLP-1, and glucagon receptors, offering significant weight loss and metabolic benefits for patients with obesity and type 2 diabetes. @@ -35,7 +26,7 @@ navigation: false ::card --- title: Cagrilintide - to: /research/peptides/cagrilintide + to: /research/cagrilintide icon: i-mdi-medication --- A cutting-edge, long-acting amylin receptor agonist that offers significant weight loss benefits and improved metabolic control for patients with obesity and type 2 diabetes. diff --git a/content/1.research/1.peptides/1.overview.md b/content/1.research/1.peptides/1.overview.md deleted file mode 100644 index 3c0c3bc..0000000 --- a/content/1.research/1.peptides/1.overview.md +++ /dev/null @@ -1,51 +0,0 @@ ---- -title: Overview -description: Peptides for weight loss and metabolic health ---- - -## Overview - -Recent advancements in peptide therapies have led to the development of three promising treatments for obesity and type 2 diabetes: tirzepatide, retatrutide, and cagrilintide. Each of these peptides offers unique mechanisms of action and significant benefits for weight loss and metabolic health. - -## Tirzepatide - -- **Mechanism**: Dual GIP/GLP-1 receptor agonist -- **Key Benefits**: - - Significant weight loss - - Improved glycemic control - - Enhanced insulin sensitivity - - Cardiovascular health benefits -- **Dosage**: Once-weekly injection, 2.5 mg to 15 mg - -## Retatrutide - -- **Mechanism**: Triple-agonist targeting GIP, GLP-1, and glucagon receptors -- **Key Benefits**: - - Substantial weight loss - - Improved glycemic control - - Enhanced metabolic function - - Potential liver health benefits -- **Dosage**: Once-weekly injection, doses explored from 1 mg to 12 mg - -## Cagrilintide - -- **Mechanism**: Long-acting amylin receptor agonist -- **Key Benefits**: - - Significant weight loss - - Enhanced satiety - - Improved glycemic control - - Potential cardiovascular benefits -- **Dosage**: Once-weekly injection, doses explored from 0.3 mg to 4.5 mg - -## Common Benefits - -All three peptides offer: -1. Substantial weight loss -2. Improved metabolic health -3. Enhanced quality of life -4. Potential long-term health benefits -5. Convenient once-weekly administration - -## Conclusion - -Tirzepatide, retatrutide, and cagrilintide represent a new frontier in the treatment of obesity and type 2 diabetes. With their unique mechanisms and impressive efficacy profiles, these peptide therapies offer hope for improved outcomes in patients struggling with weight management and metabolic disorders. diff --git a/content/1.research/1.peptides/_index.md b/content/1.research/1.peptides/_index.md deleted file mode 100644 index 566f90a..0000000 --- a/content/1.research/1.peptides/_index.md +++ /dev/null @@ -1,14 +0,0 @@ ---- -title: Peptides -description: Learn about peptides, their structure, and their role in the body. ---- - -::card-group - ::card - --- - title: Tirzepatide - to: /research/peptides/tirzepatide - --- - Explore the benefits of Tirzepatide - :: -:: diff --git a/content/1.research/1.peptides/2.tirzepatide.md b/content/1.research/2.tirzepatide.md similarity index 100% rename from content/1.research/1.peptides/2.tirzepatide.md rename to content/1.research/2.tirzepatide.md diff --git a/content/1.research/1.peptides/3.cagrilintide.md b/content/1.research/3.cagrilintide.md similarity index 100% rename from content/1.research/1.peptides/3.cagrilintide.md rename to content/1.research/3.cagrilintide.md diff --git a/content/1.research/1.peptides/4.retatrutide.md b/content/1.research/4.retatrutide.md similarity index 100% rename from content/1.research/1.peptides/4.retatrutide.md rename to content/1.research/4.retatrutide.md From 2858ab806813891554a143bc890465907161b7da Mon Sep 17 00:00:00 2001 From: kevin olson Date: Sun, 8 Sep 2024 22:26:34 -0500 Subject: [PATCH 2/2] =?UTF-8?q?=F0=9F=8E=A8=20adding=20dosage=20as=20well?= MIME-Version: 1.0 Content-Type: text/plain; charset=UTF-8 Content-Transfer-Encoding: 8bit --- content/1.research/1.index.md | 7 ++++++ content/1.research/5.dosage.md | 43 ++++++++++++++++++++++++++++++++++ 2 files changed, 50 insertions(+) create mode 100644 content/1.research/5.dosage.md diff --git a/content/1.research/1.index.md b/content/1.research/1.index.md index ee8cd60..207f499 100644 --- a/content/1.research/1.index.md +++ b/content/1.research/1.index.md @@ -31,4 +31,11 @@ position: 1 --- A cutting-edge, long-acting amylin receptor agonist that offers significant weight loss benefits and improved metabolic control for patients with obesity and type 2 diabetes. :: + ::card + --- + title: Dosage + to: /research/dosage + icon: i-mdi-medication + --- + Explore the optimal dosage regimens for our peptide therapeutics, including Tirzepatide, Retatrutide, and Cagrilintide, to maximize efficacy and minimize adverse events. :: diff --git a/content/1.research/5.dosage.md b/content/1.research/5.dosage.md new file mode 100644 index 0000000..1bfa72f --- /dev/null +++ b/content/1.research/5.dosage.md @@ -0,0 +1,43 @@ +--- +title: Dosage Information +description: Comprehensive dosage guidelines for Tirzepatide, Retatrutide, and Cagrilintide, including when to consider dose increases. +--- + +## Tirzepatide Dosage + +| Dose Level | Weekly Dosage | +|------------|---------------| +| Starting | 2.5 mg or 5 mg| +| Level 1 | 7.5 mg | +| Level 2 | 10 mg | +| Maximum | 15 mg | + +## Retatrutide Dosage + +| Dose Level | Weekly Dosage (Example) | +|------------|-------------------------| +| Starting | 1 mg or 2 mg | +| Level 1 | 4 mg | +| Level 2 | 8 mg | +| Maximum | 12 mg | + +## Cagrilintide Dosage + +| Dose Level | Weekly Dosage (Example) | +|------------|-------------------------| +| Starting | 0.3 mg or 0.6 mg | +| Level 1 | 1.2 mg | +| Level 2 | 2.4 mg | +| Maximum | 4.5 mg | + +## When to Increase Dosage + +For all peptides (Tirzepatide, Retatrutide, and Cagrilintide), consider increasing the dosage if/when you feel the current dose is not as effective as it once was. Signs that may indicate a need for dose increase include: + +1. Plateauing weight loss +2. Increased appetite or reduced feelings of fullness +3. Diminished effects on blood sugar control (for patients with diabetes) + +Always consult with your healthcare provider before making any changes to your dosage. They will evaluate your individual response, tolerability, and overall health status to determine if a dose increase is appropriate and safe for you. + +Remember that dose increases should be gradual and follow the recommended titration schedule for each medication. Your healthcare provider will guide you through this process to minimize side effects and optimize the benefits of your treatment.